Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 27 articles:
HTML format
Text format



Single Articles


    March 2018
  1. HU X, Mei S, Meng W, Xue S, et al
    CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30221.
    PubMed     Text format     Abstract available


  2. FARAONI I, Aloisio F, De Gabrieli A, Consalvo MI, et al
    The poly(adp-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by nf-kappab activation.
    Cancer Lett. 2018 Mar 8. pii: S0304-3835(18)30197.
    PubMed     Text format     Abstract available


    February 2018
  3. VELA M, Corral D, Carrasco P, Fernandez L, et al
    Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
    Cancer Lett. 2018 Feb 22. pii: S0304-3835(18)30172.
    PubMed     Text format     Abstract available


  4. HE Y, Sun L, Xu Y, Fu L, et al
    Combined inhibition of PI3Kdelta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    Cancer Lett. 2018;420:49-59.
    PubMed     Text format     Abstract available


    January 2018
  5. DE COLA A, Franceschini M, Di Matteo A, Colotti G, et al
    N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
    Cancer Lett. 2018;412:272-282.
    PubMed     Text format     Abstract available


    October 2017
  6. WEN S, Wang J, Liu P, Li Y, et al
    Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30650.
    PubMed     Text format     Abstract available


    September 2017
  7. COLLADO R, Puiggros A, Lopez-Guerrero JA, Calasanz MJ, et al
    Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30536.
    PubMed     Text format     Abstract available


  8. SADRAS T, Heatley SL, Kok CH, Dang P, et al
    Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
    Cancer Lett. 2017 Sep 1. pii: S0304-3835(17)30521.
    PubMed     Text format     Abstract available


    August 2017
  9. PRIGOZHINA TB, Szafer F, Aronin A, Tzdaka K, et al
    Fn14.TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
    Cancer Lett. 2017;400:99-109.
    PubMed     Text format     Abstract available


    July 2017
  10. MOHARRAM SA, Shah K, Khanum F, Marhall A, et al
    Efficacy of CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
    Cancer Lett. 2017 Jul 26. pii: S0304-3835(17)30455.
    PubMed     Text format     Abstract available


    April 2017
  11. ESPINOZA JL, Elbadry MI, Taniwaki M, Harada K, et al
    The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30288.
    PubMed     Text format     Abstract available


    February 2017
  12. GAZI M, Moharram SA, Marhall A, Kazi JU, et al
    The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Cancer Lett. 2017 Feb 1. pii: S0304-3835(17)30077.
    PubMed     Text format     Abstract available


  13. PIAO J, Takai S, Kamiya T, Inukai T, et al
    Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Cancer Lett. 2017;386:131-140.
    PubMed     Text format     Abstract available


    December 2016
  14. TURPIN J, Alais S, Marcais A, Bruneau J, et al
    Whole body clonality analysis in an aggressive STLV-1 associated leukemia (ATLL) reveals an unexpected clonal complexity.
    Cancer Lett. 2016 Dec 26. pii: S0304-3835(16)30785.
    PubMed     Text format     Abstract available


  15. WU Y, Giaisi M, Kohler R, Chen WM, et al
    Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model.
    Cancer Lett. 2016 Dec 18. pii: S0304-3835(16)30763.
    PubMed     Text format     Abstract available


    October 2016
  16. GUPTA P, Kathawala RJ, Wei L, Wang F, et al
    PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Cancer Lett. 2016 Oct 5. pii: S0304-3835(16)30567.
    PubMed     Text format     Abstract available


    September 2016
  17. HE SJ, Shu LP, Zhou ZW, Yang T, et al
    Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells.
    Cancer Lett. 2016 Sep 6. pii: S0304-3835(16)30491.
    PubMed     Text format     Abstract available


    April 2016
  18. HUANG A, Ju H, Liu K, Zhan G, et al
    Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
    Cancer Lett. 2016 Apr 28. pii: S0304-3835(16)30276.
    PubMed     Text format     Abstract available


  19. LU JW, Wang AN, Liao HA, Chen CY, et al
    Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30217.
    PubMed     Text format     Abstract available


    March 2016
  20. GARCIA-ALEGRIA E, Lafita-Navarro MC, Aguado R, Garcia-Gutierrez L, et al
    NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.
    Cancer Lett. 2016 Mar 2. pii: S0304-3835(16)30105.
    PubMed     Text format     Abstract available


  21. GERGES S, Rohde K, Fulda S
    Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.
    Cancer Lett. 2016 Mar 1. pii: S0304-3835(16)30108.
    PubMed     Text format     Abstract available


    February 2016
  22. SALEH AM, Taha MO, Aziz MA, Al-Qudah MA, et al
    Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.
    Cancer Lett. 2016 Feb 23. pii: S0304-3835(16)30096.
    PubMed     Text format     Abstract available


  23. SHINOHARA H, Kumazaki M, Minami Y, Ito Y, et al
    Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.
    Cancer Lett. 2016;371:1-11.
    PubMed     Text format     Abstract available


    January 2016
  24. HUANG H, Jiang X, Wang J, Li Y, et al
    Identification of MLL-fusion/MYC dash, verticalmiR-26 dash, verticalTET1 signaling circuit in MLL-rearranged leukemia.
    Cancer Lett. 2016 Jan 11. pii: S0304-3835(16)00003.
    PubMed     Text format     Abstract available


    December 2015
  25. ELGEHAMA A, Chen W, Pang J, Mi S, et al
    Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Cancer Lett. 2015 Dec 22. pii: S0304-3835(15)00765.
    PubMed     Text format     Abstract available


  26. LIU X, Li Y, Wen L, Tao K, et al
    ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell.
    Cancer Lett. 2015;369:222-8.
    PubMed     Text format     Abstract available


  27. BINATO R, de Almeida Oliveira NC, Du Rocher B, Abdelhay E, et al
    The molecular signature of AML mesenchymal stromal cells reveals candidate genes related to the leukemogenic process.
    Cancer Lett. 2015;369:134-43.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: